Announced interim results from its ongoing MuGard Phase 4 scientific trial in oral mucositis.

The trial is normally continuing to sign up patients and Gain access to anticipates presenting scientific data at a respected oncology supportive care meeting this summer. Access initiated the Stage 4 clinical trial of MuGard this year 2010 with first sites opened and topics enrolled in the first quarter of 2011. The designed trial is a prospective rigorously, randomized, multi-middle, double-blind, placebo-controlled study to judge the efficacy of MuGard in controlling symptoms caused by oral mucositis in subjects receiving chemoradiation therapy for the treatment of cancers of the head and neck.This meant there is not a regular, predictable response from trial to trial. Therefore, in the people with autism, there is significant intra-individual variability, with responses varying from strong to weak. Non-autistic adults had consistent and replicable responses from trial to trial. This shows that there can be something very fundamental that’s modified in the cortical responses in individual’s with autism, said co-writer Marlene Behrmann, professor of psychology at CMU and a leading expert on using human brain imaging to understand autism. And, what I believe is so powerful is that we sampled visual, auditory and somatosensory senses. We were unbelievably thorough and attacked every sensory modality and showed the same pattern of unreliability across all three senses.